Glass House Brands Announces Hemp Research and Development Agreement with the University of California, Berkeley
Glass House Brands (GLASF) has announced a groundbreaking research collaboration with UC Berkeley focused on hemp development. The partnership will explore medicinal product development, hemp genetics improvement, market analysis, supply chain sustainability, and AI automation for cultivation.
The research aims to develop treatments targeting coronaviruses, pain, sleep, inflammation, and cirrhosis. Glass House, which obtained a hemp license in 2024, operates a dedicated R&D greenhouse with an annual capacity of 240,000 pounds of biomass production.
The collaboration will also evaluate data-driven approaches to hemp policy and regulation to reduce uncertainty for California hemp growers. The company positions itself to potentially become one of the largest hemp cultivators in the United States, pending Federal Farm Bill developments and state-level regulatory alignment.
Glass House Brands (GLASF) ha annunciato una collaborazione di ricerca innovativa con UC Berkeley focalizzata sullo sviluppo della canapa. Il partenariato esplorerà lo sviluppo di prodotti medicinali, il miglioramento della genetica della canapa, l'analisi di mercato, la sostenibilità della catena di approvvigionamento e l'automazione tramite intelligenza artificiale per la coltivazione.
La ricerca mira a sviluppare trattamenti mirati ai coronavirus, al dolore, al sonno, all'infiammazione e alla cirrosi. Glass House, che ha ottenuto una licenza per la canapa nel 2024, gestisce una serra dedicata alla R&D con una capacità annuale di 240.000 libbre di produzione di biomassa.
La collaborazione valuterà anche approcci basati sui dati per la politica e la regolamentazione della canapa per ridurre l'incertezza per i coltivatori di canapa della California. L'azienda si posiziona per diventare potenzialmente uno dei più grandi coltivatori di canapa negli Stati Uniti, in attesa degli sviluppi del Federal Farm Bill e dell'allineamento normativo a livello statale.
Glass House Brands (GLASF) ha anunciado una colaboración de investigación innovadora con UC Berkeley centrada en el desarrollo de cáñamo. La asociación explorará el desarrollo de productos medicinales, la mejora de la genética del cáñamo, el análisis de mercado, la sostenibilidad de la cadena de suministro y la automatización con inteligencia artificial para el cultivo.
La investigación tiene como objetivo desarrollar tratamientos dirigidos a coronavirus, dolor, sueño, inflamación y cirrosis. Glass House, que obtuvo una licencia de cáñamo en 2024, opera un invernadero dedicado a I+D con una capacidad anual de 240,000 libras de producción de biomasa.
La colaboración también evaluará enfoques basados en datos para la política y regulación del cáñamo para reducir la incertidumbre para los cultivadores de cáñamo de California. La empresa se posiciona para convertirse potencialmente en uno de los mayores cultivadores de cáñamo en los Estados Unidos, a la espera de desarrollos en el Federal Farm Bill y la alineación regulatoria a nivel estatal.
글래스 하우스 브랜드 (GLASF)는 UC 버클리와의 혁신적인 연구 협력을 발표했습니다. 이 파트너십은 대마초 개발에 중점을 두고 있으며, 의약품 개발, 대마초 유전자 개선, 시장 분석, 공급망 지속 가능성 및 재배를 위한 인공지능 자동화를 탐구할 것입니다.
연구는 코로나바이러스, 통증, 수면, 염증 및 간경변을 목표로 하는 치료법을 개발하는 것을 목표로 하고 있습니다. 2024년에 대마초 라이센스를 취득한 글래스 하우스는 연간 240,000파운드의 바이오매스 생산 능력을 갖춘 전용 연구개발 온실을 운영하고 있습니다.
협력은 또한 캘리포니아 대마초 재배자들을 위한 불확실성을 줄이기 위해 데이터 기반 접근 방식을 평가할 것입니다. 이 회사는 연방 농업 법안의 발전과 주 차원의 규제 정렬에 따라 미국에서 가장 큰 대마초 재배자 중 하나가 될 가능성을 모색하고 있습니다.
Glass House Brands (GLASF) a annoncé une collaboration de recherche révolutionnaire avec UC Berkeley axée sur le développement du chanvre. Ce partenariat explorera le développement de produits médicinaux, l'amélioration de la génétique du chanvre, l'analyse de marché, la durabilité de la chaîne d'approvisionnement et l'automatisation par l'intelligence artificielle pour la culture.
La recherche vise à développer des traitements ciblant les coronavirus, la douleur, le sommeil, l'inflammation et la cirrhose. Glass House, qui a obtenu une licence de chanvre en 2024, exploite une serre de R&D dédiée avec une capacité annuelle de 240 000 livres de production de biomasse.
La collaboration évaluera également des approches basées sur les données pour la politique et la réglementation du chanvre afin de réduire l'incertitude pour les cultivateurs de chanvre de Californie. L'entreprise se positionne pour devenir potentiellement l'un des plus grands cultivateurs de chanvre aux États-Unis, en attendant les développements du Federal Farm Bill et l'alignement réglementaire au niveau des États.
Glass House Brands (GLASF) hat eine bahnbrechende Forschungskooperation mit UC Berkeley angekündigt, die sich auf die Entwicklung von Hanf konzentriert. Die Partnerschaft wird die Entwicklung von medizinischen Produkten, die Verbesserung der Hanfgenetik, Marktanalysen, Nachhaltigkeit der Lieferkette und KI-Automatisierung für den Anbau untersuchen.
Die Forschung zielt darauf ab, Behandlungen gegen Coronaviren, Schmerzen, Schlaf, Entzündungen und Zirrhose zu entwickeln. Glass House, das 2024 eine Hanflizenz erhalten hat, betreibt ein spezielles F&E-Glashaus mit einer jährlichen Kapazität von 240.000 Pfund Biomasseproduktion.
Die Zusammenarbeit wird auch datengestützte Ansätze zur Hanfpolitik und -regulierung bewerten, um die Unsicherheit für Hanfbauern in Kalifornien zu verringern. Das Unternehmen positioniert sich, um möglicherweise einer der größten Hanfbauern in den Vereinigten Staaten zu werden, abhängig von den Entwicklungen des Federal Farm Bill und der regulatorischen Abstimmung auf staatlicher Ebene.
- Significant production capacity of 240,000 pounds of hemp biomass annually
- Strategic research partnership with prestigious UC Berkeley
- Potential to become one of the largest hemp cultivators in the US
- Diversification into hemp market with multiple potential medical applications
- Success dependent on uncertain Federal Farm Bill developments
- Regulatory alignment at state level still pending
- Research outcomes and commercial viability remain uncertain
LONG BEACH, Calif. and TORONTO, April 09, 2025 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the "Company") (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX: GHBWF), one of the fastest-growing, vertically integrated cannabis companies in the U.S., today announced a collaboration with the University of California, Berkeley, to explore hemp-related research, including novel medicinal product development, identification and improvement of hemp genetics, market analysis, supply chain sustainability, and AI automation for cultivation and production.
In addition, the collaboration aims to evaluate data-driven and evidence-based approaches to hemp policy and regulation, with the aim of reducing uncertainty for California hemp growers. This collaboration will explore potential drug development research opportunities targeting coronaviruses, pain, sleep, inflammation, and cirrhosis.
In 2024, Glass House obtained a hemp license and has been actively growing and testing hemp on an R&D basis. Within the Company’s dedicated hemp R&D greenhouse, Glass House has the capacity to produce up to 240,000 pounds of biomass annually.
“We are excited to work with UC Berkeley as we continue to evaluate our long-term hemp strategy. This is the first collaboration of its kind in this industry, and Berkeley has a successful history of assisting industry stakeholders to find innovative and sustainable solutions to environmental issues. We are confident that through this agreement, we will be better positioned to navigate the local and national legislative uncertainty for the hemp industry as we prepare to scale the business into the future,” said Kyle Kazan, Co-Founder, Chairman and CEO of Glass House Brands. “Furthermore, we appreciate that the premier public university in California is supporting this sector of the agricultural industry, which is substantial in our state. We have the capacity to be one of the largest hemp cultivators in the United States, so we are excited to explore the potential benefits of this collaboration for farmers, the industry and for the state of California. We believe that the demand for hemp-derived products nationally is massive. Pending future developments with the Federal Farm Bill and regulatory changes that align at the state level, we are confident that opportunities to scale to the national market will manifest.”
Orrin Devinsky, MD, Glass House’s Medical and Science Advisor to the Board of Directors and a Professor of Neurology, Neuroscience and Psychiatry, who was the lead investigator in the studies on cannabidiol leading to FDA approval said, “As a long-time proponent of cannabinoids for treatments, I’m excited to collaborate with the research faculty at UC Berkeley to explore the development of new treatments to improve the quality of life for many with disabling disorders.”
About Glass House Brands
Glass House is one of the fastest-growing, vertically integrated cannabis companies in the U.S., with a dedicated focus on the California market and building leading, lasting brands to serve consumers across all segments. From its greenhouse cultivation operations to its manufacturing practices, from brand-building to retailing, the Company's efforts are rooted in the respect for people, the environment, and the community that co-founders Kyle Kazan, Chairman and CEO, and Graham Farrar, Board Member and President, instilled at the outset. Whether it be through its portfolio of brands, which includes Glass House Farms, PLUS Products, Allswell and Mama Sue Wellness or its network of retail dispensaries throughout the state of California, which includes The Farmacy, Natural Healing Center and The Pottery, Glass House is committed to realizing its vision of excellence: outstanding cannabis products, produced sustainably, for the benefit of all. For more information and company updates, visit www.glasshousebrands.com/ and https://ir.glasshousebrands.com/contact/email-alerts/.
Forward Looking Statements
This news release contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as "forward-looking statements"). Forward-looking statements reflect current expectations or beliefs regarding future events or the Company's future performance or financial results. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward- looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "continues", "forecasts", "projects", "predicts", "intends", "anticipates", "targets" or "believes", or variations of, or the negatives of, such words and phrases or state that certain actions, events or results "may", "could", "would", "should", "might" or "will" be taken, occur or be achieved. Forward-looking statements in this news release include, without limitation, statements regarding the Company's financial outlook or operational plans and statements related to future market conditions. All forward-looking statements, including those herein, are qualified by this cautionary statement. Although the Company believes that the expectations expressed in such statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the statements. Accordingly, readers should not place undue reliance on forward-looking statements. There are certain factors that could cause actual results to differ materially from those in the forward-looking information, including those risks disclosed in the Company's Annual Information Form available on SEDAR+ at www.sedarplus.ca and in the Company's Form 40-F available on EDGAR at www.sec.gov. For more information on the Company, investors are encouraged to review the Company's public filings on SEDAR+ at www.sedarplus.ca. The forward-looking statements in this news release speak only as of the date of this news release or as of the date or dates specified in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.
For further information, please contact:
Glass House Brands Inc.
Jon DeCourcey, Vice President of Investor Relations
T: (781) 724-6869
E: ir@glasshousebrands.com
Investor Relations Contact:
KCSA Strategic Communications
Phil Carlson
T: 212-896-1233
E: GlassHouse@kcsa.com
FAQ
What is the production capacity of Glass House Brands' (GLASF) hemp R&D greenhouse?
What medical conditions will Glass House Brands (GLASF) research target in their UC Berkeley collaboration?
When did Glass House Brands (GLASF) obtain their hemp license?
What are the main focus areas of the Glass House Brands (GLASF) and UC Berkeley research partnership?
